The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation

Blood

Volumn 87, Issue 6, 1996, Pages 2594-2603

  Lucas, Kenneth G ^a   Small, Trudy N ^a   Heller, Glenn ^a   Dupont, Bo ^a   O'Reilly, Richard J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DILUTION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOPROLIFERATIVE DISEASE; MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 0029915469     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.6.2594.bloodjournal8762594     Document Type: Article

References (46)

1. Tosato G: The Epstein Barr virus and the immune system. Adv Cancer Res 49:75, 1987
2. Rowe M, Young LS, Crocker J, Stokes H, Henderson S, Rickinson AB: Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: Implications for the pathogenesis of EBV-positive lymphomas in man J Exp Med 173.147, 1991
3. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR, Arthur DC, Patton DF, Greenberg JS, Burke B, Ramsay NKC, McGlave P, Filipovich AH: Epstein-Barr virus associated B-cell lymphoproliferative disorders following bone marrow transplantation. Blood 71:1234, 1988
4. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, Durnam DM: Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72:520, 1988
5. Antin JH, Bierer BE, Smith BR, Ferrara J, Guinan EC, Sieff C, Golan DE, Macklis RM, Tarbell NJ, Lynch E, Reichert TA, Blythman H, Bouloux C, Rappeport JM, Burakoff SJ, Weinstein HJ: Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: Effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 78:2139, 1991
6. Joncas JH, Russo P, Brochu P, Simard P, Brisebois J, Dube J, Marton JH, Leclerc JM, Hume H, Rivard GE: Epstein-Barr virus polymorphic B-cell lymphoma associated with leukemia and with congenital immunodeficiencies. J Clin Oncol 8:378, 1990
7. Cohen JI: Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine 70:137, 1991
8. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E, Cohen JI: Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321:1080, 1989
9. Nalesnik MA, Jaffe R, Starzl TE: The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 133:173, 1988
10. Shibata D, Weiss LM, Nathwani BN, Brynes RK, Levine AM: Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin's lymphoma. Blood 77:1527, 1991
11. Martin PJ, Shulman HM, Schubach WH, Hansen JA, Fefer A, Miller G, Thomas ED: Fatal Epstein-Barr virus-associated proliferation of donor B-cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Ann Intern Med 101:310, 1984
12. Fischer A, Blanche S, LeBidois J, Bordigon P, Garnie JN, Niaude P, Morine F, LeDiest F, Fischer AM, Griscelli C, Hirn M: Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 324:1451, 1991
13. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Balfour HH Jr, Simmons RL, Najarian JS: Acyclovir therapy of Epstein-Barr virus-induced post-transplant lymphoproliferative diseases. Transplant Proc 17:89, 1985
14. Shapiro RS, Chauvenet A, McGuire W, Pearson A, Craft AW, McGlave P, Filipovich A: Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin N Engl J Med 318:1334, 1988
15. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Kernan NA, O'Reilly RJ: Infusions of donor leukocytes as treatment of Epstein-Barr virus associated lymphoproliferative disorders complicating allogeneic marrow transplantation. N Engl J Med 330:1185, 1994
16. Biggs JC, Szer J, Crilley P, Atkinson K, Downs K, Dodds A, Concannon AJ, Avalos B, Tutschka P, Kapoor N, Brodsky I, Topolsky D, Bulova SI, Copelan EA. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 80:1352, 1992
17. 131I-195/busulfan/cyclophosphamide (BU/CY) in patients with advanced/refractory myeloid malignancies. Blood 82:80a, 1993 (abstr, suppl 1)
18. Dinsmore R, Kirkpatrick D, Flomenberg N, Gulati S, Kapoor N, Shank B, Reid A, Groshen S, O'Reilly RJ: Allogeneic bone marrow transplantation for patients with acute lymphoblastic leukemia. Blood 62:381, 1983
19. Forman SJ, Blume KG, Krance RA, Miner PJ, Metter GE, Hill LR, O'Donnell MR, Nademanee AP, Snyder DS: A prospective randomized study of acute graft-vs-host disease in 107 patients with leukemia: Methotrexate/prednisone vs cyclosporine/prednisone. Transplant Proc 19:2605, 1987
20. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986
21. Reisner Y, Freidrich W, Fabian IA: A shorter procedure of preparation of E-rosette bone marrow for transplantation. Transplantation 42:312, 1986
22. Young JW, Papadopoulos EB, Cunningham I, Castro-Malaspina H, Flomenberg N, Carabasi MH, Gulati SC, Brochstein JA, Heller G, Black P, Collins NH, Shank B, Kernan NA, O'Reilly RJ: T-cell depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission Blood 79:3380, 1992
23. Henle W, Henle G, Horowitz CA: Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Hum Pathol 5.551, 1974
24. Bourgault I, Gomez A, Gomard E, Levy JP: Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes. Clin Exp Immunol 84:501, 1991
25. Langhorne J, Lindahl KF: Limiting dilution analysis of precursors of cytotoxic T lymphocytes. Immunol Methods 2:221, 1981
26. Taswell C: Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol Methods 72:29, 1984
27. Flomenberg N, Hansen JA, Klein JS, Dupont B: Joint reports: T cell recognition of HLA class I molecules. Background, goals, and experimental design, in Dupont B (ed): Immunobiology of HLA, vol 1. New York, NY, Springer-Verlag, 1989, p 443
28. Efron B, Tibshirani RJ: An Introduction to the Bootstrap. New York, NY, Chapman & Hall, 1993
29. Prentice RL, Kalbfleish JD, Peterson AV, Fluornoy N, Farewell VT, Breslow NE: The analysis of failure times in the presence of competing risks. Biometrics 34:541, 1978
30. Sprent J, Tough DF: Lymphocyte life-span and memory. Science 265:1395, 1994
31. Keever CA, Small TN, Flomenberg N, Heller G, Pekle K, Black P, Pecora A, Gillio A, Kernan NA, O'Reilly RJ: Immune reconstitution following bone marrow transplantation. Comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood 73:1340, 1989
32. Ault KA, Antin JH, Ginsburg D, Orkin SH, Rappaport JM, Keohan ML, Martin P, Smith BR: Phenotype of recovering lymphoid cell populations after marrow transplantation. J Exp Med 161:1483, 1985
33. Crawford DH, Mulholland N, Iliescu V, Hawkins R, Powles R: Epstein-Barr virus infection and immunity in bone marrow transplant recipients. Transplant 42:50, 1986
34. Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, O'Reilly RJ: Clonable T lymphocytes in T cell-depleted bone murrow transplants correlate with development of graft vs host disease. Blood 68:770, 1986
35. Tomkinson BE, Maziarz R, Sullivan JL: Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis. J Immunol 143:660, 1989
36. Keever CA, Welte K, Small T, Levick J, Sullivan M, Hauch M, Evans RL, O'Reilly RJ: Interleukin 2-activated killer cells in patients following transplants of soybean lectin-separated and E-rossette depleted bone marrow. Blood 70:1893, 1987
37. Welte K, Keever CA, Levick J, Bonilla MA, Merluzzi VJ, Mertelsmann R, Evans R, O'Reilly RJ: Interleukin-2 production and response to interleukin-2 by peripheral blood mononuclear cells from patients receiving soybean lectin-separated and T-cell depleted bone marrow. Blood 70:1595, 1987
38. Ho M, Jaffe R, Miller G, Breinig MK, Dummer JS, Makowka L, Atchison RW, Karrer F, Nalesnik MA, Starzl RE: The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplant 45:719, 1988
39. Rickinson AB, Young LS, Rowe M: Influence of the Epstein-Barr virus nuclear antigen EBNA-2 on the growth phenotype of virus-transformed B cells. J Virol 61:1310, 1987
40. Frank D, Cesarman E, Liu YF, Michler RE, Knowles DM: Posttransplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus. Blood 85:1396, 1995
41. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C: Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 83:2715, 1994
42. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM: Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332:1186, 1995
43. Boyle TJ, Berend KR, DiMaio JM, Coles RE, Via DF, Lyerly HK: Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery 114:218, 1993
44. Lacerda JF, Dennig D, Lucas K, Collins N, Ladanyi M, Papadopoulos EB, O'Reilly RJ: Adoptive immunotherapy with human Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes (CTL) for the treatment of severe combined immunodeficiency (SCID) mice bearing human EBV-induced B-cell lymphoproliferative disorders (EBV-LPD). Blood 84:398a, 1994 (abstr, suppl 1)
45. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9, 1995
46. Servida P, Rossini S, Traversari C, Ferrari G, Bonini C, Nobili N, Vago L, Faravelli A, Vanzulli A, Mavilio F, Bordignon C: Gene transfer into peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity in a patient affected by EBV-induced lymphoma. Blood 82:214a, 1993 (abstr, suppl 1)